Importantly, combining arginine-intrinsic (ASS1-KD) and -extrinsic (AFD) deprivation with ruxolitinib gavage treatments in 4T1-bearing mice, starting on day 11 when 4T1 tumors are palpable, significantly reduced tumor size (Figure 4D,E). This evidence concerns the gene ASS1 and neoplasm.